Gastrointestinal Stromal Tumors: Surgical and Medical Therapy
- 1 January 2013
- book chapter
- Published by Springer Nature
- p. 115-126
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trialThe Lancet Oncology, 2010
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer, 2007
- Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal TumorAnnals of Surgery, 2007
- Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal TumorsAnnals of Surgery, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998